🌟 Could a new treatment approach redefine care for head and neck cancer?
Recent advancements in neoadjuvant chemoimmunotherapy, specifically combining nivolumab with chemotherapy, showcase a remarkable 53% deep response rate in advanced HPV-negative head and neck squamous cell carcinoma. This innovative strategy not only improves survival rates but also significantly reduces toxic side effects for patients.
Curious about how this could change treatment protocols? Dive into the full article for deeper insights!
#SyenzaNews #oncology #HealthcareInnovation